Imaging of Solid Tumors Using FAP-2286

Inclusion Criteria11

• Age >= 18 years.
• Histopathologically confirmed solid tumors in one of the following cohorts:
• a. Cohort 1 (n=11): measurable disease is not required for this cohort.
• i. Agnostic to tumor type.
• b. Cohort 2 (n=95): Metastatic disease present on conventional imaging defined as having RECIST 1.1 measurable disease or multiple bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.
• i. Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, or colon cancer.
• ii. Pathologically confirmed cancer other than noted above (basket subgroup, n=10).
• c. Cohort 3 (n=85): No evidence of metastatic disease as defined as the absence of RECIST 1.1 measurable disease or bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.
• i. Participants can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Participants may also be imaged after definitive therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and/or prognosis.
• ii. Pathologically confirmed head and neck cancer or bladder cancer.
• Ability to understand a written informed consent document, and the willingness to sign it.